Scoping Review: Perbandingan Cure Rate Obat-obat Antiskabies di Formularium Nasional dengan Non-Formularium Nasional

Rizki Amalia Nashuha, Satryo Waspodo, Yani Triyani

Abstract


Skabies adalah penyakit kulit yang disebabkan oleh tungau Sarcoptes scabiei var. hominis. Di Indonesia, skabies merupakan urutan ketiga dari 12 penyakit kulit tersering. Terdapat sebelas faktor yang dapat memengaruhi prevalensi skabies di suatu komunitas salah satunya adalah kegagalan pengobatan. Penelitian ini bertujuan mengetahui perbandingan cure rate obat-obat antiskabies di Formularium Nasional dengan Non-Formularium Nasional. Metode penelitian ini adalah scoping review yang dilakukan dari bulan September–Desember 2020. Pencarian sistematis artikel dilakukan melalui database elektronik, yaitu PubMed, Science Direct, Springer Link, Google Scholar, dan Cochrane sesuai dengan kriteria inklusi dan tidak termasuk eksklusi serta dilakukan skrining menggunakan kriteria PICOS (Pasien, Intervention, Comparison, Outcome, dan Study). Dari hasil pencarian, terdapat 17 artikel yang sesuai dengan kriteria inklusi. Dari 17 artikel, 12 artikel menunjukkan bahwa permethrin merupakan obat yang memiliki cure rate lebih baik daripada benzyl benzoate, ivermectin, gamma benzene hexachloride, dan crotamiton. Dua artikel menunjukkan ivermectin memiliki cure rate lebih tinggi daripada lindane dan sulfur. Satu artikel menunjukkan terapi kombinasi sulfur lebih baik daripada terapi tunggal. Satu artikel menunjukkan bahwa Tinospora cordifolia memiliki cure rate yang tinggi. Satu artikel menunjukkan bahwa afoxolaner dapat dijadikan obat antiskabies. Simpulan, cure rate permethrin tinggi sehingga permethrin dapat dijadikan terapi utama skabies.

 

SCOPING REVIEW: CURE RATE COMPARISON OF ANTISCABIETIC DRUGS OF NATIONAL FORMULARY AND NON-NATIONAL FORMULARY

Scabies is a skin disease caused by the mite Sarcoptes scabiei var. hominis. In Indonesia, scabies is the third of the 12 most common skin diseases. Eleven factors can influence the prevalence of scabies in a community, one of which is treatment failure. This study aims to compare the antiscabies drugs cure rate in the National Formulary with the National Non-Formularium. The research method is a scoping review conducted from September–December 2020. Article systematic searched were carried out through electronic databases, namely PubMed, Science Direct, Springer Link, Google Scholar, and Cochrane by the inclusion criteria and not exclusion and screening using the PICOS criteria (Patient, Intervention, Comparison, Outcome, and Study). From the search results, 17 articles matched the inclusion criteria. From 17 articles, 12 articles show that permethrin has a better cure rate than benzyl benzoate, ivermectin, gamma benzene hexachloride, and crotamiton. Two articles show that ivermectin has a higher cure rate than lindane and sulfur. One article suggests sulfur combination therapy is preferable to single therapy. One article shows that Tinospora cordifolia has a high cure rate. One article shows that afoxolaner can be used as an antiscabies drug. The conclusion is that permethrin has a high cure rate, so permethrin can be used as the main therapy for scabies.


Keywords


Antiscabietic drugs; Formularium Nasional; National Formulary; obat antiskabies; scabies; skabies

Full Text:

PDF

References


Mading M, Sopy IIPB. Kajian aspek epidemiologi skabies pada manusia. J Penyakit Bersumber Binatang. 2015;2(2):9–18.

World Health Organization. Scabies [Internet]. Geneva: WHO; 16 Agustus 2020 [diunduh 6 Januari 2021]. Tersedia dari: https://www.who.int/news-room/fact-sheets/detail/scabies.

Putri YY, Astuti RDI, Bhatara T. Karakteristik tanda kardinal penyakit skabies pada santri di pesantren. JIKS. 2020;2(3):126–9.

Bahrudin F, Djajakusumah TS, Susanti Y. Angka kejadian dan karakteristik pasien skabies di Rumah Sakit Al-Islam Bandung. Pros Pendidik Dr. 2015;1(2):1023–8.

Naftassa Z, Putri TR. Hubungan jenis kelamin, tingkat pendidikan dan pengetahuan terhadap kejadian skabies pada santri Pondok Pesantren Qotrun Nada Kota Depok. Biomedika. 2018;10(2):115–9.

Heukelbach J, Feldmeier H. Scabies. Lancet. 2006;367(9524):1767–74.

Handayani N, Ikaditya L. Analisis biaya efektif terapi skabies permetrin 5% dan salep 2–4. Media Informasi. 2020;15(2):89–95.

Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/813/2019 tentang Formularium Nasional.

Khalil S, Abbas O, Kibbi AG, Kurban M. Scabies in the age of increasing drug resistance. PLoS Negl Trop Dis. 2017;11(11):e0005920.

Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venerol Leprol. 2012;78(5):605–10.

Rao MA, Raza N, Faheem M, Saleem MA. Comparison of efficacy of permethrin 5% cream with crotamiton 10% cream in patients with scabies. J Ayub Med Coll Abbottabad. 2019;31(2):230–2.

Meenakshi M, Sadhna K, Neeraj S, Deepak V, Renu P. An open label, randomized, comparative study of antiscabietic drugs permethrin, gamma benzene hexachloride and ivermectin in patients of uncomplicated scabies. Int J Pharmacol Clin Sci. 2014;3(2):15–21.

Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, dkk. Mass drug administration for scabies control in a population with endemic disease. N Engl J Med. 2015;373(24):2305–13.

Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. Ann Parasitol. 2015;61(2):79–84.

Ranjkesh MR, Naghili B, Goldust M, Rezaee E. The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies. Ann Parasitol. 2013;59(4):189–94.

Sharma R, Singal A. Topical permethrin and oral ivermectin in the management of scabies: a prospective, randomized, double blind, controlled study. Indian J Dermatol Venerol Leprol. 2011;77(5):581–6.

Pourhasan A, Goldust M, Rezaee E. Treatment of scabies, permethrin 5% cream vs. crotamiton 10% cream. Ann Parasitol. 2013;59(3):143–7.

Mila-Kierzenkowska C, Woźniak A, Krzyzyńska-Malinowska E, Kałuzna L, Wesołowski R, Poćwiardowski W, dkk. Comparative efficacy of topical pertmehrin, crotamiton and sulfur ointment in treatment of scabies. J Arthropod Borne Dis. 2017;11(1):1–9.

Zaelany AI, Astuti ISW, Sutejo IR. Perbandingan efektivitas sabun sulfur 10% dengan salep 2–4 sebagai pengobatan tunggal dan kombinasi pada penyakit skabies. J Agromedicine Med Sci. 2017;3(3):19–23.

Goldust M, Rezaee E, Raghifar R, Naghavi-Behzad M. Ivermectin vs. lindane in the treatment of scabies. Ann Parasitol. 2013;59(1):37–41.

Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol. 2013;59(2):79–84.

Goldust M, Rezaee E, Raghifar R, Naghavi-Behzad M. Comparison of permethrin 2.5 % cream vs. Tenutex emulsion for the treatment of scabies. Ann Parasitol. 2013;59(1):31–5.

Goldust M, Alipour H. Permethrin 5% cream versus oral afoxolaner for the treatment of scabies a prospective, randomized, controlled, clinical trial study. Australas J Dermatol. 2019;60(Suppl 1):42–2.

Chitti Babu G, Bagati KD, Agarwal P, Sharda S. A comparative study to assess the efficacy of permethrin (topical) and ivermectin (oral) in scabies patients seeking care at a tertiary care teaching hospital of northern India. Int J Res Pharm Sci. 2020;11(1):1155–9.

Chitti Babu G, Bagati KD, Agarwal P, Sharma J. A comparative study to assess the efficacy of permethrin (topical) and benzyl benzoate (topical) for the treatment of scabies patients. Int J Res Pharm Sci. 2019;10(4):3688–93.

Castillo AL, Osi MO, Ramos JDA, De Francia JL, Dujunco MU, Quilala PF. Efficacy and safety of Tinospora cordifolia lotion in Sarcoptes scabiei var hominis-infected pediatric patients: a single blind, randomized controlled trial. J Pharmacol Pharmacother. 2013;4(1):39–46.




DOI: https://doi.org/10.29313/jiks.v3i2.7458

Refbacks

  • There are currently no refbacks.



eISSN: 2656-8438


View My Stats 


Flag Counter

Jurnal Integrasi Kesehatan dan Sains is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.